



## ResApp to Host Investor Q&A Conference Call

**Brisbane, Australia, 4 February 2019** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, will host an investor Q&A conference call on **Tuesday 5 February at 11am AEST (noon AEDT)**. With significant regulatory approval milestones due in the first half of the calendar year this Q&A is to provide shareholders an opportunity to ask ResApp's CEO and Managing Director, Tony Keating questions about ResApp's commercialisation strategy for 2019.

### Conference Call Details:

Date: Tuesday 5 February, 11am AEST (noon AEDT)

Conference ID: 5494 636

Access:

- Australia: +61 2 8038 5221
- New Zealand: 0800 452 782
- China: 4001 203 085
- Hong Kong: 800 908 865
- Singapore: 800 616 2288
- United Kingdom: 0808 234 0757
- United States: 1855 293 1544

Participants will need to provide their name and to ask a question, they will need to dial “\*1” (star, 1) on their telephone keypad. Shareholders are also encouraged to send questions via email prior to the conference call to [ir@resapphealth.com.au](mailto:ir@resapphealth.com.au).

A recording will be available four hours after the end of the call on [openbriefing.com](http://openbriefing.com).

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent

**ResApp Health Limited** ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E [info@resapphealth.com.au](mailto:info@resapphealth.com.au) W [www.resapphealth.com.au](http://www.resapphealth.com.au)



care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

**Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)